SNPs and taxane toxicity in breast cancer patients

Pharmacogenomics

Volumn 15, Issue 15, 2014, Pages 1845-1858

  Bosó, Virginia ^a,b   Herrero, María José ^a,b   Santaballa, Ana ^a   Palomar, Laura ^a   Megias, Juan E ^a,b   De La Cueva, Helena ^a   Rojas, Luis ^c   Marqués, María Remedios ^a   Poveda, José Luis ^a   Montalar, Joaquin ^a   Aliño, Salvador F ^a,d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

breast neoplasms; drug related adverse reactions; genetic polymorphism; pharmacogenetics; taxoids

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FILGRASTIM; FLUOROURACIL; GENOMIC DNA; GLUTAMINE; LYSINE; MONOCLONAL ANTIBODY; PACLITAXEL; REACTIVE OXYGEN METABOLITE; BRIDGED COMPOUND; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TAXANE; TAXOID;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYP2C8 GENE; CYP3A4 GENE; DIARRHEA; DNA REPAIR; DRUG METABOLISM; ERCC1 GENE; FEBRILE NEUTROPENIA; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAND FOOT SYNDROME; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL MUCOSITIS; PHARMACOGENETICS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; VOMITING; ADVERSE DRUG REACTION; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; GENETICS; PATHOLOGY;

AGED; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CYTOCHROME P-450 CYP3A; DNA-BINDING PROTEINS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDONUCLEASES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MIDDLE AGED; MUCOSITIS; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; TAXOIDS;

EID: 84919793480     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.127     Document Type: Article

References (50)

1. International Agency for Research on Cancer (IARC). www.iarc.fr
2. Hertz DL, McLeod HL, Hoskins JM. Pharmacogenetics of breast cancer therapies. Breast 18(Suppl 3), S59-S63 (2009
3. Tan S-H, Lee S-C, Goh B-C, Wong J. Pharmacogenetics in breast cancer therapy. Clin. Cancer Res. 14(24), 8027-8041 (2008
4. Longo R, D'Andrea M, Sarmiento R, Gasparini G. Pharmacogenetics in breast cancer: Focus on hormone therapy, taxanes, trastuzumab and bevacizumab. Expert Opin. Investig. Drugs 19(Suppl 1), S41-S50 (2010
5. Hong K-W, Oh B. Overview of personalized medicine in the disease genomic era. BMB Rep. 43(10), 643-648 (2010
6. Deenen MJ, Cats A, Beijnen JH, Schellens JHM. Part 1: Background, methodology, and clinical adoption of pharmacogenetics. Oncologist 16(6), 811-819 (2011
7. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: Pathways to personalized medicine. Clin. Cancer Res. 14(24), 7988-7999 (2008
8. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4(4), 253-265 (2004
9. Rodríguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 11(5), 621-623 (2010
10. Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J. Pharmacogenetics of taxanes: Impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 13(16), 1979-1988 (2012
11. Hertz DL. Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics 14(9), 1065-1084 (2013
12. Bosch TM, Huitema ADR, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin. Cancer Res. 12(19), 5786-5793 (2006
13. Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 42(17), 2893-286 (2006
14. Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7(5), 362-365 (2007
15. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25(29), 4528-4535 (2007
16. Gréen H, Söderkvist P, Rosenberg P, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 104(2), 130-137 (2009
17. Leskelä S, Jara C, Leandro-García LJ, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 11(2), 121-129 (2011
18. Hertz DL, Roy S, Motsinger-Reif AA, et al. CYP2C8 3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann. Oncol. 24(6), 1472-1478 (2013
19. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 99(5), 967-972 (2008
20. Varbiro G, Veres B, Gallyas F, Sumegi B. Direct effect of taxol on free radical formation and mitochondrial permeability transition. Free Radic. Biol. Med. 31(4), 548-558 (2001
21. Pan Z, Avila A, Gollahon L. Paclitaxel induces apoptosis in breast cancer cells through different calcium - regulating mechanisms depending on external calcium conditions. Int. J. Mol Sci. 15(2), 2672-2694 (2014
22. Morel Y, Barouki R. Repression of gene expression by oxidative stress. Biochem. J. 342(Pt 3), 481-496 (1999
23. Raza H, John A. 4-hydroxynonenal induces mitochondrial oxidative stress, apoptosis and expression of glutathione S-Transferase A4-4 and cytochrome P450 2E1 in PC12 cells. Toxicol. Appl. Pharmacol. 216(2), 309-318 (2006
24. Edvardsen H, Brunsvig PF, Solvang H, et al. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J. 10(6), 513-523 (2010
25. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (2009). http://evs.nci.nih.gov
26. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414-417 (2012
27. PharmGKB. www.pharmgkb.org
28. MySequenom Tools. www.mysequenom.com/tools
29. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8(5), 391-401 (1998
30. Monsarrat B, Chatelut E, Royer I, et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab. Dispos. 26(3), 229-233 (1998
31. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597-607 (2001
32. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13(6), 725-732 (2008
33. Oshiro C, Marsh S, McLeod H, Carrillo MW, Klein T, Altman R. Taxane pathway. Pharmacogenet. Genomics 19(12), 979-983 (2009
34. Baker SD, Verweij J, Cusatis GA, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85(2), 155-163 (2009
35. Rizzo R, Spaggiari F, Indelli M, et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res. Treat. 124(2), 593-598 (2010
36. Cortejoso L, García MI, García-Alfonso P, et al. Differential toxicity biomarkers for irinotecan- And oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother. Pharmacol. 71(6), 1463-1472 (2013
37. Lu X, Liu Y, Yu T, et al. ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes. PLoS ONE 8(4), e60006 (2013
38. Marsh S. Pharmacogenomics of taxane/platinum therapy in ovarian cancer. Int. J. Gynecol. Cancer. 19(Suppl 2), S30-S34 (2009
39. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-Arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21), 3540-3546 (2009
40. Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106(11), 2421-2427 (2006
41. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis 21(4), 551-555 (2000
42. Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: Very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet. Genomics 23(12), 721-728 (2013
43. Smith HE, Jones JP, Kalhorn TF, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet. Genomics 18(11), 943-953 (2008
44. Kirchheiner J, Meineke I, Fuhr U, Rodríguez-Antona C, Lebedeva E, Brockmöller J. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 9(3), 277-288 (2008
45. Kim HS, Kim M-K, Chung HH, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study. Gynecol. Oncol. 113(2), 264-269 (2009
46. Glynn SA, Boersma BJ, Howe TM, et al. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clin. Cancer Res. 15(12), 4165-4173 (2009
47. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13(3), 145-157 (2003
48. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291(1-3), 1-9 (2012
49. Kim HK, Zhang YP, Gwak YS, Abdi S. Phenyl N-Tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology 112(2), 432-439 (2010
50. Grau JJ, Caballero M, Campayo M, et al. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope 119(8), 1484-1490 (2009